 | Up a level |
Digklia, A; Kollár, A; Dietrich, D; Kronig, M N; Britschgi, C; Rordorf, T; Joerger, M; Krasniqi, F; Metaxas, Y; Colombo, I; Ribi, K; Rothermundt, C (2024). SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial. European journal of cancer, 197(113470), p. 113470. Elsevier 10.1016/j.ejca.2023.113470
Aeppli, S; Schmaus, M; Eisen, T; Escudier, B; Grünwald, V; Larkin, J; McDermott, D; Oldenburg, J; Porta, C; Rini, B I; Schmidinger, M; Sternberg, C N; Rothermundt, C; Putora, P.M. (2021). First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. ESMO open, 6(1), p. 100030. BMJ 10.1016/j.esmoop.2020.100030
Rothermundt, C; von Rappard, J; Eisen, T; Escudier, B; Grünwald, V; Larkin, J; McDermott, D; Oldenburg, J; Porta, C; Rini, B; Schmidinger, M; Sternberg, C N; Putora, Paul Martin (2017). Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithms. World journal of urology, 35(4), pp. 641-648. Springer 10.1007/s00345-016-1903-6
